Octagon Capital Advisors LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$740.1M2026 Q3+ $10.6M options (notional, not included)
Positions26
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.82.5%
What Changed This Quarter?
Top Holdings
DNTH
Dianthus Therapeutics
19.8%
ABVX
Abivax S.A.
13.1%
DFTX
Definium Therapeutics
12.7%
COGT
Cogent Biosciences
10.0%
AVBP
ArriVent BioPharma
8.6%
TSHA
Taysha Gene Therapies
6.3%
OBX
Obsidian Therapeutics
4.4%
KYMR
Kymera Therapeutics
3.1%
New / Increased
2 new · 1 increased
OBXNEW
Obsidian Therapeutics
4.4%
TNGXNEW
Tango Therapeutics
2.1%
AVBP
Arrivent Biopharma
8.6%
+8.6%
Reduced / Exited
14 reduced · 3 sold out
GOSS
Gossamer Bio
0.2%
-98.8%
DFTX
Definium Therapeutics
12.7%
-14.9%
MIRM
Mirum Pharmaceuticals
1.9%
-50.0%
DNTH
Dianthus Therapeutics
19.8%
-8.4%
KYMR
Kymera Therapeutics
3.1%
-33.9%
ALMSEXIT
Alumis
7.2%
SMMTEXIT
Summit Therapeutics
1.6%
Context Thera…EXIT
Context Therapeutics
0.2%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.